In a move aimed at advancing their mission of combating malaria and further expanding their research endeavors, 60 Degrees Pharmaceuticals (60P) has announced a public offering pricing of $2.4 million. The funds generated from this offering will be utilized for various purposes including working capital, the relaunch of their flagship product ARAKODA for malaria prevention, and further research initiatives.
Malaria, a life-threatening disease caused by parasites transmitted through mosquito bites, continues to be a major global health concern, particularly in developing countries. The World Health Organization estimates that in 2019 alone, there were about 229 million malaria cases worldwide, resulting in approximately 409,000 deaths. 60P has been at the forefront of efforts to combat this disease, developing innovative solutions and investing in research to eradicate malaria.
The public offering of $2.4 million signifies the company’s commitment to fulfilling its mission and expanding its reach. The allocated funds will provide much-needed working capital, enabling 60P to sustain and further develop their operations. Additionally, a significant portion of the funds will be utilized for the relaunch of ARAKODA, an important preventive medication for malaria.
ARAKODA, a once-daily pill that provides effective protection against malaria, has shown tremendous potential in reducing the burden of this disease. It is expected that the relaunch of ARAKODA will not only aid in the expansion of 60P’s presence in malaria-endemic regions but also contribute to the prevention and reduction of malaria cases worldwide.
Moreover, a portion of the funds raised through the public offering will be dedicated to research initiatives. 60P has always emphasized the critical role of research in finding new and improved strategies for malaria prevention and treatment. By investing in research, the company aims to advance understanding of the disease, discover innovative approaches, and, ultimately, help save lives.
The announcement of this public offering demonstrates 60P’s commitment to its core mission of combating malaria and highlights its dedication to improving global public health. By utilizing the funds for working capital, relaunching ARAKODA, and investing in research, the company aims to make significant strides in the fight against malaria.
Comments